Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 10,535 matching trials from the live ClinicalTrials.gov search.

Filters: Active, not recruiting Clear all

Conditions: Cutaneous Venous Malformations
Interventions: QTORIN 3.9% rapamycin anhydrous gel; Drug
Lead sponsor: Palvella Therapeutics, Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: Irvine, California • Palo Alto, California • Aurora, Colorado + 7 more

Conditions: Obesity
Interventions: Semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years to 15 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 26
States / cities: Escondido, California • Orlando, Florida • Tallahassee, Florida + 22 more

Conditions: HIV
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 21 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Durvalumab, Tremelimumab, Pemetrexed, Pembrolizumab, Carboplatin, Cisplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 47
States / cities: Beverly Hills, California • La Jolla, California • Los Alamitos, California + 40 more

Conditions: Breast Cancer Stage IIB
Interventions: Hydroxychloroquine, Everolimus; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Unruptured Wide-neck Aneurysms
Interventions: Citadel Embolization Device; Device
Lead sponsor: Stryker Neurovascular; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 25
States / cities: Los Angeles, California • San Francisco, California • Walnut Creek, California + 18 more

Conditions: Pre-Exposure Prophylaxis of HIV Infection
Interventions: Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years and older
Enrollment: 3,292 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 60
States / cities: Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 43 more

Conditions: Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
Interventions: Evolocumab, Routine Lipid Management; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 6,019 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 81
States / cities: Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 73 more

Conditions: ER+ HER2- Advanced Breast Cancer
Interventions: AZD9833, AZD9833 with palbociclib, AZD9833 with everolimus, AZD9833 with abemaciclib, AZD9833 with capivasertib, AZD9833 with ribociclib, AZD9833 with anastrozole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 5
States / cities: Aurora, Colorado • Sarasota, Florida • Philadelphia, Pennsylvania + 2 more

Conditions: Age-related Macular Degeneration, Age-related Maculopathy
Interventions: Observational-1, Observational-2; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 49 Years and older
Enrollment: 603 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • Pittsburgh, Pennsylvania

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Venetoclax, Ibrutinib; Drug
Lead sponsor: Michael Choi; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Amyotrophic Lateral Sclerosis
Interventions: CK0803, Excipient; Biological · Other
Lead sponsor: Cellenkos, Inc.; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: New York, New York • Houston, Texas

Conditions: Thrombophilia
Interventions: No intervention; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 1,000 participants
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Oropharyngeal Dysphagia
Interventions: Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR); Drug
Lead sponsor: Peter Belafsky, MD; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Ischemic Stroke
Interventions: OsciPulse, Intermittent Pneumatic Compression; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glioblastoma Multiforme
Interventions: Dichloroacetate (DCA), Genotype; Drug · Genetic
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Baltimore, Maryland • Winston-Salem, North Carolina

Conditions: Prostatectomy
Interventions: Magnesium sulfate; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Oligometastatic Esophageal Adenocarcinoma, Oligometastatic Gastric Adenocarcinoma, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
Interventions: Capecitabine, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin, Radiation Therapy; Drug · Radiation
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 453
States / cities: Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 276 more

Conditions: Hypophosphatasia
Interventions: ALXN1850, asfotase alfa; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Hartford, Connecticut • Baltimore, Maryland • Minneapolis, Minnesota + 3 more

Conditions: HER2-positive Breast Cancer
Interventions: Standard of Care Adjuvant Breast Radiation, Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation; Radiation · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 40 Years and older
Enrollment: 1,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2037
U.S. locations: 413
States / cities: Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 286 more

Conditions: Cancer Survivors, Chronic Disease, Physical Activity, Cancer Survivorship, Physical Inactivity, Physical Activity in Adults
Interventions: mHealth/sFitRx, Fitness Tracker; Other
Lead sponsor: The University of Tennessee, Knoxville; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Postural Tachycardia Syndrome, Postural Orthostatic Tachycardia Syndrome
Interventions: Inspiratory Threshold Device (Res-Q-Gard ITD), Sham Inspiratory Threshold Device; Device
Lead sponsor: Alfredo Gamboa; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity, Intraventricular Hemorrhage, Retinopathy of Prematurity (ROP)
Interventions: OHB-607; Drug
Lead sponsor: OHB Neonatology Ltd.; Industry
Eligibility: 0 Hours to 24 Hours
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 24
States / cities: Little Rock, Arkansas • California City, California • Los Angeles, California + 19 more

Conditions: Conditions Influencing Health Status, Healthy, Prostate Cancer
Interventions: laboratory biomarker analysis, transrectal prostate biopsy; Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 243 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2027
U.S. locations: 5
States / cities: Arcadia, California • Duarte, California • Glendora, California + 2 more

Search by objective public record fields.

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations

STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

Safety and Survival of Genetically Modified White Blood Cells in HIV-infected Twins The Gemini Study

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

Citadel Embolization Device Study

Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

GARM II: A Study on the Genetics of Age-related Maculopathy

Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

Regulatory T Cells for Amyotrophic Lateral Sclerosis

Fertility, Hypercoagulability, and Inflammation (FREYA) Registry

Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia

OsciPulse D-dimer Pilot Trial

Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)

Magnesium Sulfate as an Adjunctive Analgesic in Prostate Surgery

Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa

Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer

Effects of Personalized Exercise Prescriptions Through Mobile Health on Physical Activity and Health Outcomes in the Cancer Survivors

Breathing Device in Postural Orthostatic Tachycardia Syndrome (POTS)

A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants

Comparing the Reliability of Expressed Prostatic Secretion (EPS) and Post Massage Urine (PMU) for the Prediction of Prostate Cancer Biopsy Outcome